Over the past 12 months, 7 insiders at LIGAND PHARMACEUTICALS INC filed 76 open-market SEC Form 4 transactions on LGND: 0 purchases worth $0 and 76 sales worth $13.2M. Insiders have been net sellers over this period. The most recent filing was on Jul 1, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 1, 26 | Andrew ReardonCLO & Secretary | SELL | 1.1K | $317.15 | $349K |
| Jun 11, 26 | Jason Aryeh | SELL | 4.5K | $250.00 | $1.1M |
| Jun 10, 26 | Jason Aryeh | SELL | 500 | $250.00 | $125K |
| Mar 23, 26 | Stephen L SabbaDirector | SELL | 1.0K | $207.87 | $208K |
| Mar 11, 26 | Octavio EspinozaChief Financial Officer | SELL | 3.1K | $225.00 | $688K |
| Mar 6, 26 | John L LamattinaDirector | SELL | 2.2K | $200.76 | $434K |
| Mar 4, 26 | Octavio EspinozaChief Financial Officer | SELL | 3.4K | $208.80 | $713K |
| Mar 4, 26 | Andrew ReardonCLO & Secretary | SELL | 1.4K | $208.87 | $301K |
| Mar 3, 26 | Stephen L SabbaDirector | SELL | 2.0K | $201.50 | $410K |
| Mar 2, 26 | John W KozarichDirector | SELL | 204 | $203.57 | $41K |
| Feb 2, 26 | John W KozarichDirector | SELL | 381 | $196.36 | $75K |
| Jan 2, 26 | John W KozarichDirector | SELL | 207 | $192.40 | $39K |
| Dec 12, 25 | Octavio EspinozaChief Financial Officer | SELL | 1.8K | $188.31 | $340K |
| Dec 1, 25 | John W KozarichDirector | SELL | 179 | $200.02 | $35K |
| Nov 7, 25 | Nancy Ryan GrayDirector | SELL | 3.6K | $205.45 | $731K |
| Nov 7, 25 | John L LamattinaDirector | SELL | 2.1K | $205.45 | $441K |
| Nov 3, 25 | John W KozarichDirector | SELL | 207 | $192.38 | $40K |
| Oct 1, 25 | John W KozarichDirector | SELL | 196 | $181.18 | $35K |
| Sep 23, 25 | Jason AryehDirector | SELL | 4.6K | $171.92 | $791K |
| Sep 2, 25 | John W KozarichDirector | SELL | 267 | $164.25 | $43K |
| Aug 1, 25 | John W KozarichDirector | SELL | 467 | $131.88 | $62K |
| Jul 10, 25 | John W KozarichDirector | SELL | 934 | $125.00 | $117K |
| Jun 23, 25 | Andrew ReardonCLO & Secretary | SELL | 500 | $114.08 | $57K |
| Jun 10, 25 | Andrew ReardonCLO & Secretary | SELL | 500 | $114.54 | $57K |
| May 15, 25 | Andrew ReardonCLO & Secretary | SELL | 1.0K | $104.00 | $104K |
| May 9, 25 | Todd C DavisChief Executive Officer | BUY | 5.5K | $105.67 | $584K |
| May 9, 25 | Octavio EspinozaChief Financial Officer | BUY | 1.0K | $104.40 | $104K |
| Mar 4, 25 | Octavio EspinozaChief Financial Officer | SELL | 5.0K | $115.03 | $575K |
| Dec 23, 24 | Octavio EspinozaChief Financial Officer | SELL | 2.1K | $116.37 | $245K |
| Nov 27, 24 | John L LamattinaDirector | SELL | 2.4K | $123.65 | $298K |
| Sep 23, 24 | Andrew ReardonCLO & Secretary | SELL | 2.0K | $99.60 | $199K |
| Sep 23, 24 | Matthew E KorenbergPresident & COO | SELL | 7.1K | $102.05 | $720K |
| Sep 20, 24 | Octavio EspinozaChief Financial Officer | SELL | 800 | $103.98 | $83K |
| Sep 20, 24 | Matthew E KorenbergPresident & COO | SELL | 6.3K | $104.10 | $653K |
| Aug 28, 24 | Andrew ReardonCLO & Secretary | SELL | 1.5K | $106.39 | $160K |
| Aug 26, 24 | Matthew E KorenbergPresident & COO | SELL | 6.2K | $106.32 | $649K |
| Aug 23, 24 | Matthew E KorenbergPresident & COO | SELL | 4.3K | $105.13 | $449K |
| Aug 22, 24 | Matthew E KorenbergPresident & COO | SELL | 1.2K | $105.54 | $122K |
| Aug 9, 24 | Matthew E KorenbergPresident & COO | SELL | 18.2K | $98.50 | $1.8M |
| Aug 8, 24 | Todd C DavisChief Executive Officer | BUY | 2.5K | $97.39 | $243K |
| May 17, 24 | Octavio EspinozaChief Financial Officer | SELL | 5.0K | $86.67 | $435K |
| May 16, 24 | Octavio EspinozaChief Financial Officer | SELL | 2.3K | $86.00 | $195K |
| May 15, 24 | Octavio EspinozaChief Financial Officer | SELL | 5.9K | $86.01 | $505K |
| May 14, 24 | Matthew E KorenbergPresident & Chief Operating | SELL | 13.6K | $85.68 | $1.2M |
| May 13, 24 | Matthew E KorenbergPresident & Chief Operating | SELL | 3.4K | $84.54 | $291K |
| May 9, 24 | Nancy Ryan GrayDirector | SELL | 934 | $83.20 | $78K |
| May 9, 24 | Andrew ReardonChief Legal Officer & | SELL | 10.0K | $83.04 | $830K |
| Mar 5, 24 | Stephen L SabbaDirector | SELL | 1.9K | $74.30 | $141K |
| Feb 28, 24 | Octavio EspinozaChief Financial Officer | SELL | 140 | $88.46 | $12K |
| Sep 22, 23 | Todd C DavisCHIEF EXECUTIVE OFFICER | BUY | 4.0K | $59.38 | $238K |
Over the past 12 months, insiders at LIGAND PHARMACEUTICALS INC filed 0 open-market purchases worth $0 and 76 sales worth $13.2M on LGND, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 1, 26.
The largest recent open-market LGND insider purchase in our data was $584K by Todd C Davis, Chief Executive Officer, filed on May 9, 25.
7 different insiders at LIGAND PHARMACEUTICALS INC filed open-market SEC Form 4 transactions on LGND over the last 12 months.
InsiderTape plots every LGND insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every LIGAND PHARMACEUTICALS INC insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →